Ventyx Biosciences (VTYX) Scheduled to Post Earnings on Thursday

Ventyx Biosciences (NASDAQ:VTYX) is set to issue its quarterly earnings data after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.67) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Ventyx Biosciences (NASDAQ:VTYX) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.08. During the same period in the previous year, the company posted ($0.62) earnings per share. On average, analysts expect Ventyx Biosciences to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Ventyx Biosciences Price Performance

Shares of Ventyx Biosciences stock opened at $4.61 on Wednesday. The stock has a market capitalization of $324.65 million, a price-to-earnings ratio of -1.40 and a beta of 0.48. The business has a 50-day moving average of $6.02 and a 200 day moving average of $4.72. Ventyx Biosciences has a 12 month low of $1.87 and a 12 month high of $40.58.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on VTYX shares. Oppenheimer upgraded shares of Ventyx Biosciences from a “market perform” rating to an “outperform” rating and set a $12.00 price objective for the company in a report on Tuesday, March 12th. Lifesci Capital raised Ventyx Biosciences from a “market perform” rating to an “outperform” rating in a research report on Wednesday, February 28th. Wells Fargo & Company upgraded Ventyx Biosciences from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $7.00 to $16.00 in a report on Tuesday, March 12th. Finally, Canaccord Genuity Group cut their price target on Ventyx Biosciences from $16.00 to $15.00 and set a “buy” rating on the stock in a report on Wednesday, March 13th. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.75.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.